How to make immunotherapy work better

Checkpoint inhibitors and similar drugs have changed how cancer is treated — but only about 1 in 7 patients respond to immunotherapy. There are still significant gaps in the scientific understanding of the immune system, which makes it difficult to predict whose immune cells can be redirected to kill cancers. 

In a new piece, two executives at Genocea —a Cambridge-based biotech developing cancer therapies — argue that there's an urgent need to learn more about immune responses. Doing so will be key to deploying immunotherapies more precisely — and making them effective for more patients. 

Read more.